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There is continued interest in developing effective and innovative treatment approaches to 
manage and improve outcomes after traumatic brain injury (TBI). Included in this, is the 
potential use of repetitive Transcranial Magnetic Stimulation (rTMS), a neuromodulatory tool 
currently recommended by the National Institute for Health and Care Excellence as a treatment 
for depression. This review considers the application of rTMS after TBI, focussing on its 
therapeutic efficacy for a broad range of sequalae, whether an optimal and safe rTMS protocol 
can be determined, and recommendations for future clinical and research work.  Five research 
databases (MEDLINE, CINAHL, PsychINFO, SCOPUS, and Web of Science) were 
electronically searched, identifying thirty empirical studies (single and multiple subject case 
reports; randomised controlled trials) for full review.  Evidence suggest that rTMS has the 
potential to be an efficacious therapeutic intervention for multiple symptoms after TBI, 
including depression, dizziness, central pain, and visual neglect. However, the picture is less 
encouraging for prolonged disorders of consciousness and mixed for cognitive outcomes. 
Overall, rTMS was well-tolerated by patients, although some incidents of side effects and 
seizures have been reported. Recommendations are made for more comprehensive guidelines 
and sufficient reporting of rTMS parameters and procedures. 
 





Traumatic brain injury (TBI) is a major cause of death and disability, with Dewan et al. 
(2018) estimating that 69 million new cases of TBI will occur worldwide each year. Occurring 
along a continuum of severity and affecting a diverse set of cortical and sub-cortical structures 
(Aharon-Peretz & Tomer, 2007; Bigler, 2001, 2007), TBI is largely heterogeneous, with no 
two cases presenting the same symptoms despite seemingly similar injuries. Chronic and 
enduring problems with cognition, executive function, behavioural control, and emotion 
regulation are common (McMillan & Wood, 2016; Williams & Wood, 2010; Williams, Wood 
& Howe, 2018), imposing serious constraints on psychosocial recovery (Alderman & Wood, 
2013). Given this, there is continued interest in developing effective and innovative treatment 
approaches to manage and improve outcomes after TBI. 
Included in this, is the potential use of repetitive Transcranial Magnetic Stimulation 
(rTMS), a neuromodulatory tool which can induce neural activity through rapidly alternating 
magnetic fields (Dhaliwal, Meek, & Modirrousta, 2015; Rossi, Hallett, Rossini, & Pascual-
Leone, 2009). Brief electrical currents run through a coil creating a magnetic field at the focal 
point of the coil, stimulating cortical neurons below (Dhaliwal et al., 2015). rTMS is versatile, 
and depending on location and frequency, can be used to either inhibit or induce local and 
remote brain activity (Ziad, 2002). Standard rTMS is typically delivered as a train of repetitive 
pulses with an identical stimulus interval (Sandrini, Umilta, & Rusconi, 2011). High-frequency 
(≥5 Hz) stimulation is thought to facilitate neuronal excitability, whilst low-frequency (<1Hz) 
stimulation shows inhibitory effects (Mansur et al., 2005; Peinemann et al., 2004; Rossi et al., 
2009). In contrast, patterned forms of rTMS (which are typically shorter in duration and linked 
to sustained changes in cortical activity; Huang, Edwards, Rounis, Bhatia, & Rothwell, 2005; 
Oberman, Edwards, Eldaief, & Pascual-Leone, 2011) normally involve a burst of three pulses 
applied at 50Hz and with an inter-burst interval of 200ms (Oberman et al., 2011), with a 
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decrease or increase in cortical excitability depending on the temporal application of the bursts. 
For example, continuous theta burst stimulation (cTBS) to decrease excitability consists of a 
40s train of uninterrupted theta burst stimulation (TBS) with a total of 600 pulses, whereas 
intermittent theta burst stimulation (iTBS) to increase cortical excitability involves a 2s train 
of TBS repeated every 10s for a total of 190s and 600 pulses (see Schicktanz et al., 2015). 
Overall, rTMS paradigms are relatively easy to administer, are non-invasive, and are typically 
well-tolerated by patients (Choi, Kwak, Lee, & Chang, 2018). Indeed, one of the major 
advantages of rTMS is its relative safety and the absence of serious adverse side-effects 
(Dhaliwal et al. 2015), although there have been some reports of increased seizure risk 
(Hufnagel et al. 1990; Wassermann et al., 1996). However, even though initial evidence 
suggests that standard and patterned forms of rTMS confer similar risk of adverse events 
occurring, it remains unclear what mechanisms or combinations thereof correspond to 
increased risk, such as frequency, duration, stimulus intensity or total number of pulses. For 
this reason, there is on-going need to thoroughly examine the safety of rTMS, including any 
potential increased risk resulting from the application of higher frequency bursts with patterned 
rTMS.  
Despite this, rTMS is currently recommended by the National Institute for Health and 
Care Excellence (National Institute for Health Care Excellence (NICE), 2015) and is approved 
by the U.S Food and Drug Administration (FDA approval K083538) as a treatment for 
depression. In addition, there has been growing interest in the potential use of rTMS as a 
therapeutic intervention for a variety of neurological disorders and conditions, including 
Parkinson’s disease (Boggio et al., 2005), stroke (Hara, Abo, Kakita, Masuda, & Yamazaki, 
2016), and Alzheimer’s disease (Haffen et al., 2012). Insight gained from such studies has led 
to a number of reports documenting the use of single- and paired-pulse transcranial magnetic 
stimulation for prognostic and diagnostic purposes after TBI (Bagnato et al., 2012; Chistyakov 
5 
 
et al., 1999; Rosanova et al., 2012). Further, the potential therapeutic efficacy of rTMS after 
TBI has started to be explored.   
Herrold et al. (2014) identified seven case studies and one non-randomised pilot study 
using rTMS to treat a specific neurological sequelae following mTBI. Different sites of 
stimulation and rTMS parameters were employed, with large heterogeneity across samples. 
Herrold et al. concluded that rTMS may be well suited for the treatment of mTBI, but noted 
the need for larger-scale studies to be conducted before firm conclusions could be drawn. 
Subsequently, Dhaliwal et al. (2015) identified eight case-studies and four multi-subject reports 
concerning the efficacy of rTMS in the treatment of symptoms following TBI. They too 
concluded that rTMS showed potential in the treatment of TBI related symptoms (e.g. 
hemispatial neglect, executive dysfunction), with rTMS generally well tolerated by patients. 
However, the authors noted that the literature was in its infancy, with not enough data available 
to draw conclusions regarding the definite efficacy of rTMS following TBI. In addition, they 
also noted a need for further improvement of safety guidelines to minimize the risk of adverse 
events, including seizure and syncope.  
Since these initial reviews, there has been a sharp increase in the number of published 
trials and reported case studies exploring the efficacy of rTMS after TBI. Consequently, we 
review the literature to consider the application of rTMS after TBI, and specifically, its efficacy 
for the remediation and rehabilitation of a broad range of symptoms and neurological sequelae. 
We place particular emphasis on exploring a broad range of sequelae, documenting short- and 
long-term outcomes, and whether an optimal and safe therapeutic rTMS protocol can be 
determined. We conclude by making a number of recommendations for future clinical and 





Records were identified by searching five electronic databases, including MEDLINE, 
CINAHL, PsychINFO, SCOPUS and Web of Science. A comprehensive list of keywords and 
search terms for two key concepts (repetitive transcranial magnetic stimulation; traumatic brain 
injury) were developed using a preliminary search by author AP (Table 1).  The search was 
conducted on 18 October 2018, and screening of results and study selection was performed 
independently in an unblinded standardised manner by two reviewers (AP and CW). Reviewers 
were aware of manuscript authorship, institution, and journal. Disagreements between 
reviewers were resolved by consensus. Mendeley was used to manage citations and 
manuscripts (https://www.mendeley.com).  
 
[Table 1 here] 
 
The search strategy (see Figure 1) identified a combined total of 792 records (electronic 
database results; handsearching; reference lists; unpublished literature - conference abstracts, 
trial reports), with automatic screening processes subsequently removing duplicate entries (n = 
276), as well as non-English language (n = 9) and/or non-human/s subject (n = 71) focussed 
articles. Remaining records (n = 436) were screened against the eligibility criteria based on 
title and abstract only, followed by a full-text review where applicable (n = 110). At this stage, 
records were excluded if they did not use rTMS or only used it for diagnostic and/or prognostic 
purposes. In addition, records with mixed samples (e.g. non-traumatic aetiologies) where data 
for participants with TBI could not be distinguished with confidence were excluded. Similarly, 
trial protocols, commentaries, conference abstracts, and records without an accessible and/or 
corresponding full-text were excluded.  
 





 Thirty empirical studies involving the use of rTMS (standard rTMS = 28, patterned 
rTMS = 2) as a therapeutic or rehabilitative intervention for symptoms and sequelae following 
TBI were retained for full review. Fourteen studies concern single- or multiple-case reports, 
with the remaining 16 involving multiple patients (e.g. randomised controlled trials). The 
majority of studies review rTMS as a stand-alone treatment, although some examine its 
effectiveness alongside existing rehabilitation practices and/or combined with a 
complementary designed therapy. Varied symptoms and sequelae are also addressed. Relevant 
methodological details from the reviewed rTMS papers are summarised in Table 2. Owing to 
the heterogeneity of TBI, detailed information concerning patient descriptions, rTMS 
protocols, and stimulation parameters are also captured. Relevant methodological details from 
the reviewed rTMS papers are summarised in Table 2. This was jointly developed by AP and 
CW, and owing to the heterogeneity of TBI, detailed information concerning patient 
descriptions, rTMS protocols and stimulation parameters were captured for each eligible 
article. AP initially charted the information and subsequently discussed and reviewed the 
captured details with CW. Any disagreements or inconsistencies in the charting process were 
resolved through discussion between the two reviewers.  
[Table 2 Here] 
 
Post-concussion Syndrome (PCS) 
 Koski et al. (2015) examined the safety and efficacy of 20 sessions of rTMS over the left 
dorsolateral pre-frontal cortex (left-DLPFC) for alleviating persistent PCS arising from mTBI 
(n = 15). The majority (80%) of patients completed the full rTMS protocol, but allowance was 
made to gradually increase stimulation intensity across sessions. Side effects were minimal and 
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at one to two weeks post-rTMS, severity of PCS had declined by an average of 14.6 points. 
Using a PCS scale change score of five points or more as indicative of change over time, nine 
of twelve completers improved, whereas one patient worsened. However, even though mean 
change scores for individual PCS symptoms showed a decline in ratings across a number of 
areas (e.g. headache, fatigue), none reached statistical significance. At three-month follow-up, 
PCS treatment gains were either stable or improved for three of eight patients assessed. For the 
remaining patients, treatment gains had dissipated or returned to baseline or worse, suggesting 
that the effects of rTMS may be of limited duration, such that maintenance sessions may be 
needed. In contrast, Rutherford et al. (2017) found no immediate benefit of 13 sessions of rTMS 
to the left-DLPFC one-month post-intervention, but a significant reduction in PCS symptoms 
in an active (n = 7) versus sham (n = 7) group at two-month follow-up. Therefore, the time 
course and stability of rTMS remains uncertain. Further, the mechanistic action by which rTMS 
may exert its effects on PCS symptoms remains unclear, although Koski et al. found 
preliminary evidence to suggest that patterns of neural activity in the DLPFC and anterior 
cingulate cortex (increase and decrease, respectively) consequent to rTMS may underlie its 
effects.   
 
Headaches 
 As rTMS has proven effective for relieving pain with central nervous system aetiologies 
(Leung et al., 2009), a series of studies explored the efficacy of rTMS in alleviating mTBI 
headaches (mTBI-HA). In a prospective case series (n = 6), Leung, Fallah, et al. (2016) found 
that four sessions of rTMS (delivered over DLPFC and/or left motor cortex - LMC) reduced 
the intensity, frequency and duration of mTBI-HA symptoms, with notable improvements 
observed for five of six patients. Similarly, two randomised control trials have also found 
alleviation of mTBI-HA symptoms after relatively short courses of rTMS. Leung, Shukla, et 
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al. (2016) allocated patients with mTBI-HA to receive either three sessions of active (n = 12) 
or sham (n = 12) rTMS over the LMC. Compared to sham, the active group reported a 
significant percentage reduction in persistent headache intensity one-week post intervention 
(50% vs. 16.6%). However, these differences were no longer evident four weeks post-
intervention. In contrast, debilitating headache exacerbation scores were significantly lower in 
the active group four weeks post-intervention, while scores for the sham group remained 
unchanged. In a subsequent RCT of similar design and sample size, Leung et al. (2018) found 
that four neuronavigated sessions of rTMS over the left-DLPFC could alleviate mTBI-HA 
symptoms over a longer time course. A significantly higher percentage of patients in receipt of 
active rather than sham rTMS no longer experienced persistent headache at one- (50% vs. 7%) 
and four-weeks (57% vs. 20%) post-intervention. Additionally, patients in the active group also 
reported lower debilitating headache and average daily persistent headache intensity scores 
one- and four-weeks post-intervention.   
 Such findings support the clinical feasibility and efficacy of a short-duration of rTMS for 
alleviating mTBI-HA, paving the way for morphological and mechanistic assessments of the 
treatment. However, the potential influence of comorbidities (e.g. depression, PTSD) on initial 
symptom perception or treatment response has yet to be explored. Stimulation of the DLPFC 
has been shown to have antidepressant effects, and consequently, the alleviation of mTBI-HA 
symptoms reported in Leung et al. (2018) may have been attributable to changes in the severity 
of depression rather than a direct effect of rTMS. In addition, neither RCT examined outcomes 
by mechanism of injury even though there is some evidence that clinical and functional 
outcomes may differ following blast versus non-blast related TBI (Greer et al., 2017; Lange, 
Iverson, Brubacher, Mädler, & Heran, 2012; Wilk et al., 2010). It also remains unclear whether 
there are any significant differences in the short- and long-term efficacy of rTMS for alleviating 




 Some patients with TBI experience persistent idiopathic post-traumatic chronic 
dizziness, leading to reduced quality of life (Chamelian & Feinstein, 2004). In a near-identical 
protocol to Koski et al. (2015), Paxman et al.  (2018) explored the efficacy of ten sessions of 
high frequency rTMS delivered over the DLPFC in a 61-year-old male with persistent (>5 
years) dizziness following mTBI. In addition to a clinically meaningful reduction in the adverse 
impact of dizziness on quality of life (Tamber, Wilhelmsen, & Strand, 2009), pre-intervention 
dizziness severity and frequency were reduced by more than 50% three-months post-
intervention, with notable improvements observed between one- and three-months; possibly 
suggesting a delayed response to rTMS. Additionally, with a cost of $C300 per session, they 
argued that ten sessions of rTMS represents a low-cost burden compared to conventional 
therapies. However, studies focussing on pathophysiology and long-term follow-up are needed 
to determine the mechanistic action of rTMS and longevity of symptom relief.  
 
Central Pain  
 Building on existing evidence concerning the efficacy of rTMS for managing various 
chronic pain conditions (Galhardoni et al., 2015), one study has examined the effects of high 
intensity rTMS for the management of medically intractable chronic pain after mTBI. Choi et 
al. (2018) found that ten sessions of high-intensity rTMS applied over the primary cortex (M1) 
resulted in a significant reduction in self-reported pain intensity and improved physical health-
related quality of life compared to a sham group, with treatment gains sustained for at least 
four-weeks. Speculating on the potential mechanisms underpinning the observed effect, they 
argued that rTMS applied to the M1 could have provided an analgesic effect by improving 
blood flow, influencing the endogenous opioid system, or by modifying abnormal 




Given the reported efficacy of rTMS for treating refractory depression in patients 
without TBI and that response rates to antidepressants have been reported to be lower following 
TBI than found in non-TBI depressed populations (Fann, Hart, & Schomer, 2009), several 
studies have explored whether rTMS can also improve mood after TBI. Fitzgerald et al. (2011) 
found a 50% reduction in Montgomery-Asperg Depression Rating Scale (MDRS; Montgomery 
& Asberg, 1979) scores after applying sequential low and high frequency stimulation to the 
right and left-DLPFC in a 41-year-old female 14-years post-TBI. Similarly,  Nielson et al. 
(2015) found that 30 sessions of low frequency rTMS over the DLPFC improved mood in a 
48-year-old male who had sustained a severe TBI five years prior. Specifically, baseline 
Hamilton Depression Rating Scale (Hamilton, 1986) scores had decreased by 49% at three-
month follow-up, representing an improvement from severe to minor depressive symptoms. A 
similarly large effect was found by Iliceto et al. (2018) who reported a 70.8% reduction in self-
reported mood symptoms from the start (assessment at one-week) to the end of a six-week (30 
sessions; DLPFC) high-frequency rTMS protocol in a 37-year-old male with severe TBI. 
However, it should be noted that no true baseline quantitative assessment of the patient’s 
depressive symptoms was taken before the onset of the rTMS protocol. In addition, there were 
also several changes to the patient’s psychiatric medication regimen that commenced around 
the start of the protocol. Consequently, determining the specific contribution of rTMS to the 
patient’s self-reported change in mood is not possible.  
Even so, a number of pilot RCTs have also reported significant reductions in depressive 
symptoms in medically stable TBI samples after rTMS. Leung et al. (2018) reported slightly 
improved mood one-week post-assessment following active rTMS, and Siddiqi et al. (2018) 
found that MDRS scores had improved by an average of 56% following 20 sessions of bilateral 
rTMS applied to the left- (high frequency) and right-DLPFC (low frequency) (n = 9) compared 
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to 27% following sham (n = 5) stimulation (Cohen’s d = 1.43). Likewise, Lee and Kim (2018) 
found that ten sessions of low-frequency rTMS applied over the right-DLPFC (n = 7) resulted 
in a 29.29% pre- to post-intervention decrease in MDRS scores compared to only 1.4% after 
sham stimulation (n = 6; effect size = 1.44). However, the active group also performed 
significantly better post-intervention on the Trail Making Test (TMT) and the Stroop Colour 
Word Test (effect size = 1.49 and 1.24 respectively). Consequently, it remains unclear whether 
the reported effect of rTMS on depressive symptomology was direct, or indirect via improved 
neurocognitive performance. In addition, none of the RCTs described above evaluated whether 
treatment gains persisted several months beyond the cessation of the rTMS protocol and all 
involved relatively small sample sizes, thereby limiting the generalisability of results. Finally, 
it should also be noted that Rutherford et al. (2017) found no significant active versus sham 
group differences in mood when assessed immediately post-intervention and at two-month 
follow-up. Instead, a likely placebo effect was noted, where MDRS scores improved slightly 
pre- to post-intervention in both groups.   
 
Cognitive 
In a case study of a 67-year-old male presenting with severe cognitive impairment 
following traumatic diffuse axonal injury, Hara et al. (2017) examined the treatment efficacy 
of 12 sessions of high frequency rTMS applied to the anterior cingulate gyrus combined with 
goal-oriented cognitive rehabilitation. Very small improvements on the Mini-Mental State 
Examination and TMT were found immediately post-treatment. These gains remained at three-
month follow-up, but performance on measures of memory remained unchanged from baseline. 
In a similar vein, Pachalska et al. (2011) examined the therapeutic effectiveness of behavioural 
training combined with two differentiated neurotherapy programmes delivered in crossover 
design (Programme A - 20 sessions of relative beta training; Programme B - 20 sessions of 
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rTMS) in a 26-year-old male with severe TBI and frontal syndrome. Over the course of the 
neurotherapy programme, the patient’s verbal and non-verbal IQ improved significantly, with 
memory functions also improving from baseline. However, most improvement occurred 
following completion of Programme B, suggesting greater efficacy of rTMS over relative beta 
training. However, given the cross over design, it is not possible to definitely ascribe treatment 
gains to rTMS alone.   
That said, improved cognitive performance has been reported when rTMS has been 
used in isolation. In addition to the findings of Lee and Kim (2018; see previous section), 
Fitzgerald et al. (2010) reported small improvements after rTMS in verbal fluency and speed 
of information processing; although they did not examine whether gains were primary or 
secondary to concurrent improvements in mood. However, both Koski et al. (2015) and 
Rutherford et al. (2017) reported no significant changes in cognitive function following rTMS. 
However, in the latter study, as most patients performed near to the maximum score on the 
Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005) at baseline, there was little 
room for improvement following the rTMS intervention.  
 
Aphasia  
 Chantsoulis et al. (2017) examined the efficacy of two differentiated neurotherapy 
programmes (see Pachalska et al., 2011) in a 29-year-old female with severe TBI and chronic 
crossed aphasia. Small improvements were seen across a number of neuropsychological 
domains (e.g. executive, language, memory) following relative beta training (programme A), 
whereas most of the patients cognitive dysfunctions had resolved (including language) after 
low and high frequency rTMS (programme B) was sequentially applied to the left or right 
frontal and temporal brain regions, respectively. Western Aphasia Battery (Kertsez, 1982) 
quotient scores improved from 21 at baseline, to 37 after Programme A and 93 after Programme 
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B. Statistically reliable changes in the physiological parameters of brain functioning were also 
recorded, including increased event-related potentials (ERPs; P1 and P2 components) from the 
first (baseline) to the second (Programme A) and third recordings (Programme B), as well as 
greater activation over the right frontal area at the third recording. However, and similar to 
Pachalska et al. (2011), given the crossover design, lack of details concerning time between 
each neurotherapy programme and the presence of behavioural training in both programmes, 
the distinct therapeutic effect of rTMS in this instance is unclear.     
 
Visuo-Spatial Attention and Neglect 
 Bonni et al. (2013) demonstrated how continuous theta burst stimulation (cTBS; chosen 
because of its ability to induce “powerful long-lasting changes in the excitability of the 
stimulated cortex”, page 1) delivered over the left posterior parietal cortex (l-PPC), could 
improve symptoms of hemispatial neglect in a 20-year-old patient with severe TBI. A two-
week course of cTBS (administered twice daily) significantly improved performance on the 
Behavioural Inattention Test (Wilson, Cockburn, & Halligan, 1987), with clinical gains still 
evident two weeks post-intervention. These clinical gains were accompanied by decreased 
excitability of the PPC-M1 connections in the left hemisphere and a bilateral increase in 
functional connectivity in the frontal parietal network. Such findings appear to lend support to 
the model of hemispheric competition as the basis of neglect (Nowak et al., 2009), and suggest 
that both micro- and macro-structural damage could have contributed to the patients 
hemispatial neglect. However, given the lack of a sham condition, and that neglect may 
originate from several cortical and subcortical sites, more rigorous systematic approaches (e.g. 





Recovery from Disorder of Consciousness (DOC)  
Using paired pulse rTMS, which incorporates excitation and cortical rest to enhance 
safety, Pape et al. (2009) found that a six-week rTMS protocol (30 sessions over the right-
DLPFC) led to incremental neurobehavioural gains in a 36-year-old male who remained in a 
vegetative state (VS) 287 days after severe TBI. The patient progressed clinically from VS at 
baseline to a Minimally Conscious State (MCS) by the 15th session of rTMS (mid-point), with 
further improvements up to the 25th session. However, neurobehavioural decline almost 
equivalent to baseline was observed between the 25th and 30th rTMS sessions; likely reflecting 
increased levels of fatigue and sleepiness observed at the time of assessment. Neurobehavioural 
follow-up at six-weeks also indicated decline in functioning compared to the 25th session, but 
was still higher than baseline and the 30th session (when fatigued). In addition, incremental 
behavioural changes were also observed, including improved ability to focus on and/or track 
objects/movement/people, vocalising single words, and using an eyes-open/closed system to 
answer yes/no questions. Moreover, the patient’s primary caregiver reported maintenance of 
neurobehavioural status one year after post-rTMS. On this basis, the authors concluded that at 
least 15 sessions of rTMS appear to be required to elicit a clinically significant change from 
VS to MCS, although noted that changing the dose and/or combining with another intervention 
could alter the time frame and therapeutic effect.  
A handful of additional studies have also examined the efficacy of rTMS for DOC, but 
they have done so in mixed samples where treatment outcomes are inconsistently examined by 
aetiology (e.g. anoxia, stroke, TBI). However, even though reported outcomes do not 
exclusively concern TBI, they nevertheless warrant discussion here as they still provide useful 
information concerning the application, and potential therapeutic efficacy, of rTMS for DOC 
after TBI. With this caveat in mind, Xia, Bai, et al. (2017) conducted a single-blinded 
prospective study with 16 patients (TBI n = 2) with MCS or UWS/VS, finding no significant 
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improvement in CRS-R scores following 20 sessions of rTMS over the left-DLPFC. Consistent 
with this, Xia, Liu, et al. (2017) also found no therapeutic effect of either a single or 20 
consecutive sessions of rTMS over the left-DLPFC in 13 patients (TBI n = 2) with DOC or 
UWS/VS. Similarly, Manganotti et al. (2013) found no significant improvements in CRS-R 
scores for three patients with TBI (VS n = 1, MSC n = 2) following a single session of high 
frequency rTMS over the left/right M1. However, significant increases in motor-evoked 
potential (MEP) amplitude were noted. Lui et al. (2016) also found no significant CRS-R 
changes following a single-session of rTMS (left M1) in patients with VS (TBI n = 2) or MCS 
(TBI n = 2) compared to a sham condition, although they noted increased peak systolic and 
mean flow velocity in patients with MCS.   
In addition, Cincotta et al. (2015) found no therapeutic effect of high frequency rTMS 
at M1 (n = 11; 2 with traumatic aetiologies) in the first randomised, sham-controlled, cross-
over study of VS. A later study by He et al. (2018) also found no significant changes in EEG 
parameters, CRS-R or Clinical Global Impression Improvement scale scores in their 
randomised, sham-controlled, cross-over study of six patients with VS, MCS/Emerging MCS, 
including four patients with traumatic aetiologies. Although, they noted that CRS-R scores 
showed slight improvement in response to both active (left M1 stimulation) and sham sessions, 
with one patient with traumatic aetiology emerging from MCS one week after active rTMS 
treatment and during a sham rTMS session. Overall, they argued that the differential response 
to rTMS reported across studies may be attributable to varying CRS-R scores on admission, 
duration of DOC, and varying aetiology. Indeed, a comparative analysis of Cincotta et al. and 
He et al. suggests that a lower admission CRS-R score, longer duration (> 9 months), and 
anoxic-ischemic encephalopathy is perhaps predictive of poorer functional outcomes and 
rTMS treatment response.   
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Even so, it should also be noted that there is generally wide variation in rTMS protocols 
(intensity, frequency, duration and site – see Table 2 for further details), existing studies are 
limited by small sample sizes, duration of DOC varies substantially, ‘awakening’ drugs are 
inconsistently terminated during rTMS protocols, and determining whether disease recovery is 
attributable to natural recovery or the rTMS intervention delivered is difficult. Further, there is 
also variation across studies concerning the assessment of minor clinical and behavioural 
responses indicative of DOC recovery, with several relying on either clinician or caregiver 
reports despite a lack of concordance often evident between the two (e.g. Cincotta et al., 2015; 
Schnakers et al., 2009). Finally, even though carry over effects were excluded in one study 
with cross-over design, it is possible that the prolonged effects of rTMS treatment may extend 
to several weeks; thus, follow-up testing is required at longer intervals. 
 
Visual and Auditory Impairments  
 Cosentino et al. (2010) found preliminary evidence of a therapeutic role of rTMS in 
reducing the frequency and intensity of post-traumatic complex auditory musical hallucinosis, 
with treatment effects persisting for at least five months. Similarly, in a 53-year-old male 
experiencing severe tinnitus after TBI with comorbid depression and alcohol abuse, Kreuzer et 
al. (2013) found that five series of low-frequency rTMS delivered over three years resulted in 
a significant reduction in tinnitus severity (i.e. loudness, subjective annoyance, tinnitus 
handicap), with treatment effects lasting three-six months each time. In the latter case study, 
rTMS was delivered over the left primary auditory cortex in the first four treatment series (ten 
sessions each) and the right-DLPFC in the final series (five sessions). The patient remained 
abstinent from alcohol and benzodiazepines during the protocol. However, as the patient was 
in receipt of antidepressant (amitriptyline) and antiepileptic (pregabalin) medication alongside 
the protocol, a beneficial indirect effect of these on tinnitus cannot be ruled out. Although, this 
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seems unlikely as they were prescribed several months prior to the rTMS protocol and their 
efficacy for tinnitus is either controversial or undocumented (Bayar, Böke, Turan, & Belgin, 
2007; Kreuzer et al., 2013). 
 Jones et al. (2018) also documented a beneficial effect of four sessions of neuronavigated 
low-frequency rTMS over pharmacological interventions for the treatment of post-TBI 
refactory binocular oscillopsia. One- to two-weeks following the second trial of rTMS in which 
visual area V5/MT was targeted bilaterally, symptomatic improvement in large-amplitude 
oscillations was observed which remained at 12-month follow-up. However, the patient 
subjectively reported experiencing no benefit from subsequent rTMS trials in terms of visual 
acuity, visual function (e.g. reading), or other functional abilities, and they continued to 
experience small-amplitude oscillations. Overall, this suggests that large- and small-amplitude 
oscillations may reflect different mechanisms, and thus, warrant different rTMS treatment 
approaches.  
 
Quality of Life 
 Mańko et al. (2013) examined the effectiveness of two neurotherapy programmes in 
patients aroused from prolonged coma after TBI, finding some support for improved quality of 
life after rTMS. However, a robust conclusion is limited due to methodological limitations and 
insufficient detail presented in the original paper.   
 
Motor Recovery 
 Cinnera et al. (2016) presented the case of a 25-year-old male who underwent 20 sessions 
of cerebellar iTBS combined with ten sessions of occupational/physical therapy, 43 months 
after sustaining a severe TBI. In this instance, iTBS was chosen as it has been previously shown 
to be effective in improving ataxic gait and posture symptoms following a cerebellar stroke 
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(Bonni, Ponzo, Caltagirone, & Koch, 2014). Improved motor and balance functions were 
recorded after rTMS, including increased walking speed (attributed to increase in right step 
length), improved balance (upper and lower limb), and improved right-sided fine and gross 
motor hand skills.  
 
Side effects/tolerability 
 TBI has generally been regarded as a contradiction for rTMS due to its association with 
increased neural excitability and subsequent seizure risk (Herman, 2002). However, the 
majority of studies reviewed here report good levels of tolerability, noting only transient and 
minimal side effects, such as headache (Koski et al., 2015), dizziness (Leung, Shukla et al., 
2016), and fatigue (Paxman et al., 2018), or none at all (e.g. Choi et al., 2018; Fitzgerald et al., 
2010; Neilson et al., 2013). Additionally, some studies report positive side effects of rTMS 
beyond the primary outcome being assessed, such as reports of less mental ‘fog’, irritability, 
and increased energy (Koski et al., 2015). Although, it should be noted that some studies did 
not explicitly address safety or confirm an absence of adverse events (e.g. Bonni et al., 2013; 
He et al., 2018; Rutherford et al., 2017).   
In contrast, a small number of studies reported more serious side effects, resulting in 
adaptation or termination of the rTMS protocol (e.g. Pape et al. 2014). Cavinto, Iaia, and 
Piccione, (2012) reported a partial and secondarily generalised tonic-clonic seizure three hours 
after the fourth daily session of an rTMS protocol conforming to existing safety guidelines 
(Wasserman, 1998). Consequently, even though occurrence of seizure is uncommon when 
using sub-threshold stimulation, it is possible that daily administration of rTMS could result in 
a long-lasting physiological cumulative effect. Namely, increasing after-discharges, triggered 
seizures, and eventually, spontaneous epileptic seizures. However, they equally noted that the 
safety guidelines did not address the maximum amount of repetitive stimulation in a single 
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treatment or procedures for inter-train intervals, with subsequent research finding that rTMS 
trains may increase the risk of seizure in patients with brain lesion, irrespective of seizure 
history (Rossi et al. 2009).  
Given such concerns, attempts have been made to monitor the occurrence or non-
occurrence of adverse events following rTMS in the context of TBI, with a view of establishing 
effective Data Safety Monitoring Plans (DSMP) to ensure both the safety of participants and 
validity of outcome data. Specifically, Pape et al. (2009) explored the efficacy (see Recovery 
from Disorders of Consciousness section) and safety of an rTMS protocol applied to a 26-year-
old male with DOC after severe TBI, developing a comprehensive DSMP including coverage 
of: (1) safety procedures (e.g. rTMS to be provided only after completion of a daily medical 
examination; EEGs conducted before and after every rTMS session); (2) safety factors (e.g. 
daily monitoring of clinical and medical variables, such as sweating, skin integrity and 
hyper/hypotension; comparison to baseline); (3) safety response plans (e.g. action to be taken 
if any safety factor changes from baseline; seizure response plan), and (4) oversight by a data 
safety monitoring board (e.g. all safety and efficacy data reported to independent experts for 
monitoring). In the case of Pape et al. (2009), no adverse events were recorded that were 
attributable to the rTMS procedure. However, the benefits of such a rigorous DSMP were 
highlighted in a subsequent study (Pape et al. 2014), where EEG recording showed an 
electrographically seizure without clinical accompaniment 40 minutes after the 21st rTMS 
session in a patient in VS. Consequently, an appropriate safety response was implemented 
(seizure medication, daily monitoring, EEG assessment) which allowed completion of an 
adapted (e.g. 19 additional rTMS sessions; 2% lower stimulation intensity 100 fewer impulses 
per session) rTMS protocol one week later. No further adverse events were noted, highlighting 
that if steps are taken to minimize risks, rTMS can be applied successfully after TBI.   
21 
 
Finally, supplementary to DSMP and generic safety guidelines (e.g. Rossi et al., 2009), 
Nielson et al. (2015) also recommended adoption of rigorous pre-screening criteria for safely 
administering rTMS in in the context of moderate to severe TBI; including exclusion of patients 
with a history of seizure; review of neuroimaging reports to ensure that stimulation can be 
safely delivered to the target region; and exclusion of those taking medications that lower 
seizure threshold and/or have metallic implants. In addition, they also advised using low-
frequency stimulation (owing to its antiepileptic effects; Hsu et al., 2011), although 
acknowledged that high-frequency stimulation may be appropriate if combined with more 
stringent eligibility criteria if anticipated treatment benefits sufficiently outweigh any increased 
risk. Further, restricting TBI patients to low-frequency stimulation protocols may be unduly 
restrictive in some instances, especially where high-frequency stimulation may be the preferred 




The 30 studies reviewed here suggest that rTMS has the potential to be an efficacious 
therapeutic intervention after TBI. Consistent improvements were documented across both 
single- and multiple-case reports and controlled trials for the treatment of depression (e.g. 
Fitzgerald et al., 2010; Iliceto et al., 2018; Siddiqi et al., 2018) and mTBI-HA (e.g. Leung et 
al., 2018; Leung, Shukla et al., 2016). There was also some promising initial evidence for a 
therapeutic effect of rTMS for the management of dizziness (Paxman et al., 2018), central pain 
(Choi et al., 2018), Aphasia (Chantsoulis et al., 2017), and visual neglect (Bonni et al., 2013) 
after TBI. However, and consistent with previous reviews (Dhaliwal et al., 2015; Herold et al., 
2014), results were less encouraging for improving states of altered consciousness (e.g. He et 
al., 2018; Manganotti et al., 2013) and mixed for cognitive outcomes (e.g. Hara et al., 2017).  
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There are a variety of factors that may have hypothetically contributed to the varied 
effectiveness of rTMS across studies and domains of outcome. For example, the diversity and 
questionable adequacy of measures used to evaluate similar outcomes across studies makes 
comparison and evaluation of results difficult, ultimately hindering understanding of which 
rTMS parameters lead to the best rehabilitation outcomes and treatment response. In addition, 
rTMS treatment protocols and stimulation parameters vary greatly across studies, with 
intervention protocols often poorly defined and lacking sufficient detail to allow full 
replication. Nevertheless, given the heterogeneous nature of TBI, it is perhaps unrealistic to 
anticipate a single, optimum or even a relatively standardised rTMS protocol across studies 
even if targeting similar symptomology. One of the advantages of rTMS is its versatility, 
arguably making it an excellent match for TBI; it allows for a personalised protocol to address 
specific clinical needs. However, this heterogeneity, especially when combined with small 
sample sizes, limits the evaluation and generalisability of results. Further, even with a similar 
protocol, one patient may respond differently to rTMS parameters and biochemical processes 
compared to another. Indeed, the influence of inter-individual variables (e.g. time post-injury; 
injury location; severity of injury; comorbidities) on treatment outcomes remains largely 
unknown. Although, even if elucidated and positive treatment gains materialise, it would still 
be difficult to determine whether observed effects are a primary or secondary response to 
rTMS. For instance, given the known antidepressant action of rTMS, it remains unclear 
whether reported cognitive improvements would persist regardless of changes in mood, or 
whether cognitive gains correlate with concurrent improvements in mood (i.e. Fitzgerald et al., 
2010). Consistent with this, previous research has provided some support for a cognitive 
neuropsychological hypothesis of antidepressant action in rTMS treatment (Boggio et al., 
2005; Schutter, Van Honk, Laman, Vergouwen, & Koerselman, 2010). 
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The varied effectiveness of rTMS across studies may also be attributable to two 
additional factors: (a) variation in cortical target, and (b) protocols for positioning the rTMS 
coil (see McClintock et al. 2018). First, proportionally, a greater number of studies opted to 
apply rTMS to normalize frontal dysfunction associated with TBI, with many choosing to 
stimulate the left/right DLPFC. For example, the DLPFC was consistently chosen as the 
cortical target for the alleviation of depressive symptomology, with consistent and favourable 
treatment responses noted.  Thus, it appears that the DLPFC may be a promising target region 
for the alleviation of depressive symptomology after TBI. Presumably, rTMS applied to the 
left DLPFC for example, induces dynamic changes throughout the central executive network, 
and in turn, alterations in connectivity with the salience and default mode networks. 
Specifically, previous research (i.e. Anderson et al., 2016) exploring the use of rTMS for the 
treatment of depression suggests that the mechanistic action is a decrease in over-activity of 
the default mode network, and enhanced activity of the salience and central executive networks, 
leading to relief of the cognitive, emotional and psychomotor symptoms that represent the 
cardinal features of depression. However, there was ultimately large variation in cortical targets 
across studies overall, with large variation sometimes evident within a single domain of 
outcome (e.g. DOC - left /right DLPFC, left/right M1; Cognitive – cingulate gyrus, left and 
right frontal and temporal; right DLPFC). Consequently, the varied effectiveness of rTMS 
noted here may be attributable, at least in part, to variation in cortical targets across studies. 
Therefore, at this stage it is difficult to draw systematic conclusions concerning what the most 
efficacious rTMS cortical targets may be to address specific symptoms/sequelae following 
TBI.  
Second, in the current set of reviewed studies, the use of neuronavigated guidance 
technologies was determinable in 28 studies, with some indication of enhanced efficacy when 
such technologies were utilised (15/16 versus 9/11). Of course, without a formal analysis of 
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such data, only a tentative conclusion can be drawn. It should also be noted that in other 
samples, there is only limited evidence suggesting that neuronavigated guidance position 
technologies confer higher efficacy rates (Fitzgerald et al., 2009). Additionally, such 
technologies are expensive, add complexity to rTMS procedures, and place additional burden 
on patients and clinical resources. However, they also allow greater precision in locating 
cortical targets (McClintock et al., 2018), are already recommended for the treatment of 
depression (Fitzgerald et al., 2009), and may also help to avoid direct stimulation of potential 
hazards (e.g. lesions or plates that could unpredictably alter the path of rTMS currents; Neilson 
et al., 2015); thereby lowering risk.    
 In relation to this, the need to develop more comprehensive safety guidelines to maximise 
safe administration of rTMS in TBI remains. In addition to DSMP (Pape et al. 2009), generic 
safety guidelines (e.g. Rossi et al., 2009), rigorous pre-screening criteria (Nielson et al., 2015), 
and compensatory steps that could be taken to mitigate risk when exceeding and/or not 
adhering to standard safety protocols (e.g. when expected potential benefits to the patient 
outweigh associated costs) should be developed. In line with some of the recommendations of 
McClintock et al. (2018), we also recommend that reports concerning the use of rTMS after 
TBI consistently document the following basic procedural elements: coil selection, location, 
method and placement; motor threshold (e.g. site and determination method); number, time 
course and duration of sessions, and basic treatment parameters (e.g. intensity and how it was 
determined from motor threshold, pulse frequency, train duration, inter-train interval, number 
of stimulations and pulses per session). Importantly, such information would promote 
consistency in the clinical application of rTMS in TBI, provide knowledge that can facilitate 
further evidence-based care, promote greater rigour in rTMS designs, and allow the potential 
effectiveness of rTMS as a therapeutic intervention after TBI to be more thoroughly evaluated. 
Finally, based on the clinical application of rTMS in other neurological populations, we also 
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recommend consideration of the use of neuroimaging and electrophysiological methods to 
document the specific effects of rTMS by identifying biomarkers that could hypothetically 
predict a patient’s response to rTMS interventions (Dionísio, Duarte, Patrício, & Castelo-
Branco, 2018). This would also support the adoption and execution of rigorous pre-screening 
criteria as recommended previously, ensuring that patients set to gain most are identified and 
receive a personalised rTMS protocol.  
 Additionally, important aspects for future work include the need to examine the longevity 
and time-course of rTMS effects. The majority of studies reviewed here assessed treatment 
outcomes immediately after the last session of rTMS and up to one month following, with only 
a handful extending beyond this time-frame (Illiceto et al., 2018; Pape et al., 2009). Given the 
life-long, debilitating nature of TBI and its higher prevalence in younger populations (Barker-
Collo, Wilde, & Feigin, 2009; Kraus & Chu, 2005), examining whether rTMS interventions 
can result in lasting therapeutic benefits is a particularly important consideration. It would also 
be of clinical and research value to explore the stability of treatment effects, and specifically, 
maintenance strategies following response or remission with rTMS. This may take the form of 
pre-determined sessions (e.g. monthly booster sessions) or adoption of a relapse treatment 
approach (e.g. re-introduce rTMS as needed based on worsening symptoms; McClintock et al., 
2018; Mennemeier et al. 2013). As with other clinical populations, further research is needed 
to systematically develop evidence-based maintenance strategies, including RCT based studies 
comparing various approaches.  
 The relative effectiveness of rTMS when used in isolation or when combined with 
conventional rehabilitation methods also remains uncertain. Based on the concept that rTMS 
elicits changes to brain plasticity that can help facilitate additional functional improvements, 
Hara et al. (2017) argued that rTMS should be used to complement current rehabilitative 
methods. Consistent with this, rTMS was commonly delivered in the reviewed studies 
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alongside traditional cognitive rehabilitation, pharmacological interventions, 
neurodevelopmental therapy, or other differentiated neurotherapy programmes. However, we 
did not evaluate the relative effectiveness of one combination of treatments compared to 
another here, as there were typically only singular instances of each combination.  Further, 
given the complex and varied needs of survivors, as well as the multifaceted nature of 
neurobehavioural rehabilitation, it is unlikely that rTMS will ever be used in complete isolation. 
Therefore, distinguishing the unique treatment effects of rTMS from those of conventional 
rehabilitation methods is always going to be difficult. To address this, rigorously designed 
RCTs are needed that include appropriate control groups. However, interpretation of treatment 
outcomes would still be difficult given the heterogeneous nature of TBI and subsequent inter-
individual variation likely to occur across groups. Consequently, it is likely that naturalistic 
studies will continue to dominate and shape the field for the foreseeable future. 
Finally, limitations with our scoping review should also be acknowledged. First, our 
results are only up to date as of 18th October 2018. Second, whilst every effort was made to 
locate all relevant studies that met our eligibility criteria, it is possible that some relevant 
literature was missed (e.g. grey literature; alternative database searches). Third, whilst the focus 
of our scoping review process was to provide a descriptive overview of a large and diverse 
body of literature, it nevertheless means that we were unable to critically synthesise outcomes 
from the different studies, rigorously assess the methodological quality of individual studies, 
or rule out the possibility of publication bias. Therefore, whilst the studies reviewed here 
indicate that rTMS has the potential to be an efficacious therapeutic intervention after TBI, 
systematic analysis of reported treatment outcomes and effect sizes need to occur before firmer 
conclusions can be drawn. However, the breadth of coverage achieved via a scoping review 
methodology, also means that we likely addressed a greater range of study designs and 
methodologies than would ordinarily have been included in a meta-analysis or systematic 
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review. Therefore, our current methodological approach arguably allowed for greater breadth 




Whilst there is not enough data to draw firm conclusions regarding the definite efficacy of 
rTMS after TBI, the studies reviewed here suggest that rTMS holds promise as a well-tolerated 
intervention for a broad range of symptoms and neurological sequalae after TBI. However, 
appropriate safety, pre-screening criteria and data monitoring guidelines need to be developed 
and consistently adopted. However, key questions remain and further naturalistic, as well as 
larger blinded, randomised, controlled trials need to be conducted. Encouragingly, our 
screening criteria identified several conference abstracts (pre-publication data), pre-trial 
registrations and RCT protocols that, when complete, will allow further systematic evaluation 
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Table 1. Search Strategy: Keywords, Phrases and Search Terms.  
CINAHL, MEDLINE, PsychINFO SCOPUS Web of Science 
Concept 1: Traumatic Brain Injury  
(CINAHL: MM “Brain Injuries+”) 
(MEDLINE: MM “Brain Injuries, 
Traumatic”) (PsychINFO: MM 
“Traumatic Brain Injury”)  
N/A N/A 
(traumatic brain injur* OR TBI) (traumatic brain injur* 
OR TBI) 
(traumatic brain injur* 
OR TBI) 
Concept 2: Repetitive Transcranial Magnetic Stimulation 
(MM “Transcranial Magnetic 
Stimulation”) 
N/A N/A 
(repetitive transcranial magnetic 
stimulation* OR rTMS OR transcranial 
magnetic stimulation* OR TMS) 
(repetitive transcranial 
magnetic stimulation* 
OR rTMS OR 
transcranial magnetic 
stimulation* OR TMS) 
(repetitive transcranial 
magnetic stimulation* 
OR rTMS OR 
transcranial magnetic 
stimulation* OR TMS) 
*Controlled Vocabulary Terms: CINAHL = CINAHL Headings, MEDLINE = Medical 




























Table 2. Summary of studies using rTMS following TBI 















Bonni et al 
(2013)+  
 
20yo M, 1 week 
coma following 
severe TBI 
24 Left PPC 
NN: 10-20 IS 
Coil: 70mm Figure-8  
2 sessions cTBS daily (15min 
interval) over 2 weeks. 3 pulse 
bursts at 50Hz/80% aMT repeated 
every 200ms for 40s.   











31yo M, state of 
coma following 
severe TBI 
8 Left DLPFC 
NN: X 
Coil: 70mm Figure-8  
10 daily sessions. 10min 









29yo F, 2 month 
coma following 
severe TBI 





20 sessions with 25 stimulations. 








Choi et al. 
(2018)* 
 
A: 3 M, 3 F, 43.2 
(9.7)yrs, S: 3 M, 
3 F, 42.0 (8.4)yrs 







Coil: Figure-8 70mm air cooled 
10 sessions. A: 20 stimulations 10 
Hz/90% MT, 5s TD, 55s ITI. S: 





(5th/10th), 1, 2 













Coil: 70mm Figure-8  
2 itBS daily for 3 weeks. 20 
stimulations, 8s ITI. Train = 10 
bursts (5Hz; 200ms int.). Burst = 













α2 M in VS, 47 & 
65 yo.  
31 & 85 Left M1 
NN: X 
Coil: Figure-8 coil 
5 sessions, 1-month washout. A: 









































41yo F, severe 
TBI, 1hr loss of 
consciousness  





Coil: Figure-8 cooled   
4 weeks, 5 daily sessions. R: 1 
train 900 pulses, 1Hz/110% rMT. 
L: 30 trains 5s TD, 10Hz/110% 













67yo M 13 ACG 
NN: TMS  
Coil: 80mm Double cone  
12 sessions (6 days, 2 weeks). 24 
stimulations, 10s TD (100 pulses), 






and 3 months 
after 
No 
He et al. 
(2018)*^ 
α2 M, 2 F, 29-49 
yo, 2 VS, 1 MCS, 
1 EMCS 
1-28 Left M1 
NN: X 
Coil: Figure-8  
5 sessions, 1 week washout. 
A: 20Hz/100% rMT, 20 trains, 50 







after and 1 
week 
NI 
Iliceto et al. 
(2018)+ 
37yo M, history 
of anxiety and 
BD, severe TBI, 
11-12 day coma  
10 Left DLPFC 
NN: X   
Coil: NI 
30 sessions (5 days, 6 weeks). 62 
mins, 6Hz/120% sMT, 4s TD, 26s 





and 2 years 
after  
No 




57yo M >240 1: Left 





Coil: Figure-8 air cooled 
1: 5 sessions (1 week) 1Hz/90% 
PT. 2 & 3: 10 sessions (2 weeks) 
1Hz/ 90% PT, 4: 5 sessions (1 
week) 1Hz/110% PT. 30 mins, 








Koski et al. 
(2015)* 
9 M, 6 F 
34.3 (1.8)yrs, 1-3 
concussions, 60% 
severe depression 
6-336 Left DLPFC 
NN: X 
Coil: Figure-8 
20 sessions (5 days, 4 weeks). 20 
















53yo M, 10 days 
unconscious, 1 
epileptic seizure 
Est. 60 1-4: Left 




Coil: Figure-8 90mm water 
cooled  
1-4: 10 sessions (12 days), 2000 
stimuli 1Hz/110% rMT. 5: 5 




3-6 months No 
Lee & Kim 
(2018)* 
A: 5 M, 2 F, 
42.42 (11.32)yrs. 
S: 4 M, 2 F, 




Coil: 70mm figure-8  
10 sessions (5 sessions, 2 weeks), 
A: 50 stimulations, 1Hz/100% 
rMT, 40 pulses per train, 25s ITI. 













A: 10 M, 2 F, 
41.2 (14)yo. S: 11 
M, 1 F, 41.4 
(11.6)yo 
NI Left MC 
NN: TMS 
 
Coil: Figure-8  
3 sessions. A: 20 trains, 100 
pulses 10Hz/80% rMT, 1s ITI. S: 












6 M, 38-60yo 48-84 (not 
full data) 
1: Left MC, 
2: Left 






4 sessions. 100 pulses 10Hz/80% 
MT, 20 trains. Sequential sessions 







Leung et al. 
(2018* 
A: 12 M, 2 F, 33 
(8)yo. S: 11 M, 4 
F, 35 (8)yo.  
NI Left DLPFC 
NN: TMS 
Coil: Figure-8 
4 sessions. A: 20 trains, 100 
pulses 10Hz/80% rMT, 1s ITI. S: 


















Coil: 70mm Figure-8 
30 sessions (5 days, 6 weeks). 300 
paired pulse trains, 100ms inter-









Pape et al. 
(2014)+ 
 
1: 54yo M, VS; 
2:  & 32yo M,  







Coil: Figure-8 70mm 
30 sessions of 300 paired pulse 
trains, 100ms inter-pulse interval, 






Lui et al. 
(2016)* 
α2 F in VS, 2 M 
in MCS, 45-63 yo 
2-28 Left M1 
NN: X 
Coil: Figure-8 coil 
1 session. A: 20 trains, 
20Hz/100% MT, 2.5s TD, 28s 
ITI. S: Coiled faced away. 
PDOC 










α2 M in MCS, 1 F 
in VS, 29-38 yo 
34-94 Left and 
right M1 
NN: MEPs 
Coil: figure-8 coil 
1 session. 1000 stimulations, 











40 patients severe 
TBI 







48yo M, severe 







30 sessions (5 days, 6 weeks). 30 













26yo M, 2 month 
coma following 
severe TBI 
Est. 36  Left/right 
front. and 
temp.   
NN: MRI 
Coil: NI 











61yo male, mTBI 60 Left DLPFC 
NN: TMS 
 








 10 sessions (2 weeks). 10 trains, 










in the last 5yrs 
<60 Left DLPFC 
NN: X 
Coil: Figure-8 
13 sessions (3 weeks). 25 bursts, 
30 1.5s TD pulses, 20Hz/100% 













A: 7 M, 2 F, 43 
(13)yo. S: 4 M, 2 








Coil: 70mm Double air cooled  
A: 20 sessions. L: 4000 pulses, 
10Hz/ 20% rMT, 5s TD, 20s ITI. 








Xia, Bai et 
al. (2017)*  
 
α1: 23yo M in 
MCS. 2: 40yo M 
in VS  
1: 13. 2: 16. Left DLPFC 
NN: X 
Coil: Figure-8  
20 sessions daily. 1000 pulses, 





after and 10 
days after 
No 
Xia, Liu et 
al. (2017)* 
α2 M, 1 F in VS, 
1 M in MCS, 23-
60 yo  
7-13 Left DLPFC 
NN: 10-20 IS 
Coil: Figure-8 
1(/20) session. 1000 pulses, 







+ = case study, ^ = cross over design, α = TBI identified from mixed sample, θ = 1 patient had an improved EEG, β =  MCS only (full sample), 
10-20 IS = 10-20 International System, ACG  = anterior cingulate cortex, ADL = activities of daily living, aMT = active motor threshold, BD = 
bipolar personality disorder type 1, cTBS = continuous theta burst stimulation,  DLPFC = dorsal lateral prefrontal cortex, DTI = diffusion tensor 
imaging, EMCS = emerged from minimally conscious state, front. = frontal lobe, ITI = inter-train interval, MC = motor cortex, MCS = 
minimally conscious state, MEP = motor-evoked potential, MRI = magnetic resonance imaging, NI = no information provided, NN = X = no 
neuronavigation available, PPC = posterior parietal cortex, RSN = resting-state networks, sMT = standard motor threshold (1.62), T = treatment 
terminated, temp. = temporal lobe, TD = train duration, VS = vegetative state                                                                                                                                                                                                                                                                                               
